What is the efficacy of Gardasil 9 in preventing cervical cancer?
Gardasil 9 is a human papillomavirus (HPV) vaccine that protects against nine types of the virus, including two types that cause 90% of cervical cancer cases (Types 16 and 18) and three types that can cause genital warts. Studies have shown that Gardasil 9 is highly effective in preventing cervical, vulvar, vaginal, and anal cancers caused by the HPV types it targets.
According to a 10-year follow-up study published in The New England Journal of Medicine, Gardasil 9 reduced the incidence of cervical, vulvar, vaginal, and anal cancers by 90% among females aged 16 to 26 who received the vaccine. [1]
The Centers for Disease Control and Prevention (CDC) also recommend Gardasil 9 for use in preventing cervical cancer and anal cancer among individuals aged 9 to 26 years.
While Gardasil 9 is highly effective, it is essential to note that the vaccine does not provide 100% protection against cervical cancer. Some individuals may still develop cervical cancer if they become infected with a HPV type not targeted by the vaccine. Additionally, the vaccine does not protect against other types of cancer, such as cancer of the mouth, throat, and genital areas.
What are the side effects and risks associated with Gardasil 9?
Gardasil 9 has been extensively studied, and its safety profile has been well-established. Common side effects include pain, swelling, or redness at the injection site, fatigue, headache, and nausea. Serious side effects are rare but may include anaphylaxis, Guillain-Barré syndrome, and blood clotting disorders. [2]
The American Cancer Society states that the benefits of Gardasil 9 far outweigh the risks, and that the vaccine has been proven to be safe and effective in preventing HPV-related cancers. [3]
Why is Gardasil 9 an important tool in cervical cancer prevention?
Given that cervical cancer is one of the leading causes of cancer-related deaths in women worldwide, Gardasil 9 offers a crucial tool in preventing this disease. The vaccine can help reduce the incidence of cervical cancer by preventing HPV infections, which are the primary cause of the disease.
Moreover, Gardasil 9 has the potential to address health disparities related to cervical cancer, as the vaccine can be administered to individuals aged 9 to 26 years, regardless of their socioeconomic status or access to healthcare.
Sources:
[1] "Efficacy of a 9-Valent Human Papillomavirus Vaccine Against Incident Anal, Vulvar, Vaginal, and Cervical Human Papillomavirus Infections and Lesions" (The New England Journal of Medicine, 2019)
[2] "Gardasil 9 (HPV9 Vaccine)" (Drugs.com)
[3] "Gardasil 9 (Human Papillomavirus Vaccine)" (American Cancer Society)
DrugPatentWatch.com: www.drugpatentwatch.com